Document text
Principal Investigator: Barton F. Haynes
Organization: DUKE UNIVERSITY
Fiscal Year: 2022
Award: $3,878,223
Funding agency: National Institute of Allergy and Infectious Diseases
While HIV-1 broadly neutralizing antibodies (bnAbs) provide potent protection from HIV-1, to date they have
been difficult to induce in the setting of vaccination. A second type of HIV-1 envelope (Env) antibodies that are
easy to induce are termed non-neutralizing antibodies (NNAbs) (because they are not bnAbs), or called
effector antibodies, because they mediate a myriad of potentially protective anti-HIV-1 effector mechanisms.
One of the 5 Phase IIb HIV-1 vaccine efficacy trials (ALVAC/AIDSVAX in RV144) showed an estimated
vaccine efficacy of 31%, with a correlate of decreased transmission risk of polyfunctional antibodies that
mediate FcR-anti-HIV-1 activities including C1 and V2-targeted ADCC. Currently there are two vaccine
efficacy trials ongoing to test the ability of an ALVAC-C, bivalent C/C gp120 boost (HVTN 702) and rAd26
prime, gp140 protein boost (HVTN 705) with hopes of inducing protective NNAbs. HVTN 702 has two wildtype
(WT) gp120 Envs as boosts, and HVTN 705 has one WT Env as boost. However, neither trial utilitize
strategies for inducing a breadth of NNAbs with boosting Env design. Thus, a key goal of current HIV-1
vaccine development is to develop the simplest and most effective vaccine that induces polyfunctional NNAbs
should either of the current efficacy trials fail to improve on RV144.
Our overall goals are 1) to develop an ADCC mosaic multivalent Env immunogen to follow an ALVAC-C
prime; and 2) to produce ADCC mosaic Env gp120s under current good manufacturing practices (CGMP)
conditions, perform toxicity studies, and prepare an investigational new drug application (IND) for testing in an
HVTN Phase I clinical trial in man.
Overall Specific Aim 1. Develop and produce a trivalent ADCC mosaic Env immunogen that can
follow an ALVAC-C prime and test them in the Animal Core in an ADCC mediating NNAb-unmutated
common ancestor (UCA) VH + VL mouse model and in a transmitted/founder (TF) tier 2, R5 SHIV
rhesus macaque study (RMs) (Drew Weissman, Project Lead; Barton Haynes, Co-I)
Overall Specific Aim 2. Produce CGMP trivalent ADCC mosaic mRNA gp120 immunogens. (Thomas
Denny Project Lead; Maureen Maughan, Project Co-I)
.
Terms: <AIDS Virus><ALVAC><ALVAC Canarypox Vector><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Algorithms><Alum Adjuvant><Animals><Antibodies><Antibody Response><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding><Cell Lineage><Contracting Opportunities><Contracts><Data><Early-Stage Clinical Trials><Encapsulated><Formulation><Goals><Grant><HIV><HIV Envelope Glycoprotein gp120><HIV Envelope Protein gp120><HIV Vaccine Trials Network><HIV env Protein gp120><HIV-1><HIV-1 vaccine><HIV-I><HIV1><HIV1 vaccine><HTLV-III gp120><HVTN><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunostimulation><Infection><Investigational New Drug Application><LAV-HTLV-III><Lead><Lymphadenopathy-Associated Virus><M mulatta><M. mulatta><Macaca><Macaca mulatta><Macaque><Mediating><Messenger RNA><Modern Man><Molecular Interaction><Mosaicism><Pb element><Phase><Phase 1 Clinical Trials><Phase I Clinical Trials><Production><Proteins><RNA immunization><RNA vaccination><Regimen><Rhesus Macaque><Rhesus Monkey><Risk><SHIV><T-Cell Epitopes><T-Cells><T-Lymphocyte><T-Lymphocyte Epitopes><Technology><Testing><Therapeutic><Toxic effect><Toxicities><Transmission><Vaccination><Vaccine Design><Vaccines><Virus-HIV><Work><Writing><alum><aluminum sulfate><antibody-dependent cellular phagocytosis><design><designing><develop a vaccine><develop vaccines><development of a vaccine><efficacy trial><expectation><experiment><experimental research><experimental study><first in man><first-in-human><gp120><gp120 ENV Glycoprotein><gp120(HIV)><heavy metal Pb><heavy metal lead><homologous recombination><immunogen><immunogenic><improved><in silico><in vivo><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA immunization><mRNA vaccination><man><man's><meetings><mosaic disorders><mouse model><murine model><neutralizing antibody><new technology><novel><novel technologies><phase 1 trial><phase I protocol><phase I trial><programs><response><simian HIV><simian human immunodeficiency virus><thymus derived lymphocyte><transmission process><vaccination study><vaccination trial><vaccine development><vaccine efficacy><vaccine strategy><vaccine study><vaccine trial>